<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0002140'>Ischemic stroke</z:hpo> is a frequent and serious disease with limited treatment options </plain></SENT>
<SENT sid="1" pm="."><plain>Platelets can adhere to hypoxic cerebral endothelial cells by binding of their <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (GP) Ib receptor to <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor </plain></SENT>
<SENT sid="2" pm="."><plain>Exposure of subendothelial matrix proteins further facilitates firm attachment of platelets to the vessel wall by binding of collagen to their GPVI receptor </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, we addressed the pathogenic role of GPIb, GPVI, and the aggregation receptor GPIIb/IIIa in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> in mice </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND RESULTS: Complete blockade of GPIb alpha was achieved by intravenous injection of 100 microg Fab fragments of the monoclonal antibody p0p/B to mice undergoing 1 hour of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>At 24 hours after transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were assessed by 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining </plain></SENT>
<SENT sid="6" pm="."><plain>In mice treated with anti-GPIb alpha Fab 1 hour before middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, ischemic lesions were reduced to approximately 40% compared with controls (28.5+/-12.7 versus 73.9+/-17.4 mm3, respectively; P&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Application of anti-GPIb alpha Fab 1 hour after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> likewise reduced brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes (24.5+/-7.7 mm3; P&lt;0.001) and improved the neurological status </plain></SENT>
<SENT sid="8" pm="."><plain>Similarly, <z:mpath ids='MPATH_63'>depletion</z:mpath> of GPVI significantly diminished the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume but to a lesser extent (49.4+/-19.1 mm3; P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Importantly, the disruption of early steps of platelet activation was not accompanied by an increase in <z:mp ids='MP_0001914'>bleeding</z:mp> complications as revealed by serial magnetic resonance imaging </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, blockade of the final common pathway of platelet aggregation with anti-GPIIb/IIIa F(ab)2 fragments had no positive effect on <z:hpo ids='HP_0001297'>stroke</z:hpo> size and functional outcome but increased the incidence of <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> and mortality after transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in a dose-dependent manner </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our data indicate that the selective blockade of key signaling pathways of platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and aggregation has a different impact on <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome and <z:mp ids='MP_0001914'>bleeding</z:mp> complications </plain></SENT>
<SENT sid="12" pm="."><plain>Inhibition of early steps of platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to the ischemic endothelium and the subendothelial matrix may offer a novel and safe treatment strategy in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>